Compare FLUX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | GDTC |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 10.4M |
| IPO Year | 2019 | 2021 |
| Metric | FLUX | GDTC |
|---|---|---|
| Price | $0.41 | $0.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.53 | N/A |
| AVG Volume (30 Days) | ★ 503.9K | 19.5K |
| Earning Date | 11-12-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.40 | $0.68 |
| 52 Week High | $7.55 | $3.68 |
| Indicator | FLUX | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 46.00 |
| Support Level | $0.40 | $0.73 |
| Resistance Level | $0.55 | $1.07 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 9.43 | 40.00 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.